Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma
Xiaoju Huang,1– 3 Mengmeng Wang,1– 3 Dan Zhang,1– 3 Chen Zhang,4 Pian Liu1– 3 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 2Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Hu...
Main Authors: | Huang X, Wang M, Zhang D, Zhang C, Liu P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-01-01
|
Series: | Journal of Hepatocellular Carcinoma |
Subjects: | |
Online Access: | https://www.dovepress.com/advances-in-targeted-drug-resistance-associated-with-dysregulation-of--peer-reviewed-fulltext-article-JHC |
Similar Items
-
Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
by: Shou-Wu Lee, et al.
Published: (2022-03-01) -
First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
by: Domenico Ciliberto, et al.
Published: (2023-08-01) -
Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
by: Lisha Mou, et al.
Published: (2021-10-01) -
Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01) -
A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario
by: Dipasquale A, et al.
Published: (2021-04-01)